Annual Cash & Cash Equivalents
$9.05 M
-$31.41 M-77.62%
December 1, 2023
Summary
- As of February 12, 2025, ORMP annual cash & cash equivalents is $9.05 million, with the most recent change of -$31.41 million (-77.62%) on December 1, 2023.
- ORMP annual cash & cash equivalents is now -88.28% below its all-time high of $77.25 million, reached on August 31, 2021.
Performance
ORMP Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$42.10 M
-$42.65 M-50.32%
September 1, 2024
Summary
- As of February 12, 2025, ORMP quarterly cash and cash equivalents is $42.10 million, with the most recent change of -$42.65 million (-50.32%) on September 1, 2024.
- Over the past year, ORMP quarterly cash and cash equivalents has increased by +$33.05 million (+364.98%).
- ORMP quarterly cash and cash equivalents is now -50.32% below its all-time high of $84.75 million, reached on June 1, 2024.
Performance
ORMP Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ORMP Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -77.6% | +365.0% |
| 3 y3 years | - | +40.9% |
| 5 y5 years | +172.0% | +1164.8% |
ORMP Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -77.6% | at low | -50.3% | +670.0% |
| 5 y | 5-year | -88.3% | +172.0% | -50.3% | +1227.8% |
| alltime | all time | -88.3% | +5039.1% | -50.3% | >+9999.0% |
Oramed Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $42.10 M(-50.3%) |
| Jun 2024 | - | $84.75 M(+356.3%) |
| Mar 2024 | - | $18.58 M(+105.1%) |
| Dec 2023 | $9.05 M(-77.6%) | $9.05 M(+65.6%) |
| Sep 2023 | - | $5.47 M(-19.2%) |
| Jun 2023 | - | $6.77 M(-71.9%) |
| Mar 2023 | - | $24.10 M(-40.4%) |
| Dec 2022 | $40.46 M(+47.4%) | $40.46 M(+21.9%) |
| Sep 2022 | - | $33.20 M(+11.1%) |
| Jun 2022 | - | $29.89 M(+6.9%) |
| Mar 2022 | - | $27.97 M(-12.3%) |
| Dec 2021 | $27.46 M(-64.5%) | - |
| Nov 2021 | - | $31.88 M(-58.7%) |
| Aug 2021 | $77.25 M(+300.3%) | $77.25 M(+34.5%) |
| May 2021 | - | $57.41 M(+69.8%) |
| Feb 2021 | - | $33.80 M(+126.4%) |
| Nov 2020 | - | $14.93 M(-22.6%) |
| Aug 2020 | $19.30 M(+479.6%) | $19.30 M(+107.2%) |
| May 2020 | - | $9.31 M(+56.9%) |
| Feb 2020 | - | $5.93 M(+87.1%) |
| Nov 2019 | - | $3.17 M(-4.7%) |
| Aug 2019 | $3.33 M(-33.4%) | $3.33 M(-15.6%) |
| May 2019 | - | $3.95 M(+15.1%) |
| Feb 2019 | - | $3.43 M(-11.2%) |
| Nov 2018 | - | $3.86 M(-22.7%) |
| Aug 2018 | $5.00 M(+25.9%) | $5.00 M(+36.0%) |
| May 2018 | - | $3.67 M(+11.5%) |
| Feb 2018 | - | $3.29 M(+161.9%) |
| Nov 2017 | - | $1.26 M(-68.3%) |
| Aug 2017 | $3.97 M(+1.6%) | $3.97 M(+129.0%) |
| May 2017 | - | $1.73 M(+19.4%) |
| Feb 2017 | - | $1.45 M(-36.6%) |
| Nov 2016 | - | $2.29 M(-41.4%) |
| Aug 2016 | $3.91 M(+21.6%) | $3.91 M(+18.3%) |
| May 2016 | - | $3.30 M(+2.2%) |
| Feb 2016 | - | $3.23 M(+65.7%) |
| Nov 2015 | - | $1.95 M(-39.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Aug 2015 | $3.21 M(+82.3%) | $3.21 M(-16.5%) |
| May 2015 | - | $3.85 M(+249.1%) |
| Feb 2015 | - | $1.10 M(-83.4%) |
| Nov 2014 | - | $6.66 M(+277.8%) |
| Aug 2014 | $1.76 M(-22.4%) | $1.76 M(-28.8%) |
| May 2014 | - | $2.47 M(-23.9%) |
| Feb 2014 | - | $3.25 M(+137.3%) |
| Nov 2013 | - | $1.37 M(-39.7%) |
| Aug 2013 | $2.27 M(-48.7%) | $2.27 M(+105.6%) |
| May 2013 | - | $1.10 M(-45.8%) |
| Feb 2013 | - | $2.04 M(-63.1%) |
| Nov 2012 | - | $5.53 M(+24.8%) |
| Aug 2012 | $4.43 M(+192.8%) | $4.43 M(+240.8%) |
| May 2012 | - | $1.30 M(-28.7%) |
| Feb 2012 | - | $1.82 M(+22.0%) |
| Nov 2011 | - | $1.50 M(-1.2%) |
| Aug 2011 | $1.51 M(+26.2%) | $1.51 M(-21.2%) |
| May 2011 | - | $1.92 M(-0.6%) |
| Feb 2011 | - | $1.93 M(+75.4%) |
| Nov 2010 | - | $1.10 M(-8.2%) |
| Aug 2010 | $1.20 M(-30.1%) | $1.20 M(+5.7%) |
| May 2010 | - | $1.13 M(+56.5%) |
| Feb 2010 | - | $724.70 K(-36.8%) |
| Nov 2009 | - | $1.15 M(-33.2%) |
| Aug 2009 | $1.72 M(-24.3%) | $1.72 M(-46.6%) |
| May 2009 | - | $3.22 M(-6.4%) |
| Feb 2009 | - | $3.44 M(+56.9%) |
| Nov 2008 | - | $2.19 M(-3.4%) |
| Aug 2008 | $2.27 M(+18.2%) | $2.27 M(-14.7%) |
| May 2008 | - | $2.66 M(+132.2%) |
| Feb 2008 | - | $1.15 M(-22.6%) |
| Nov 2007 | - | $1.48 M(-22.9%) |
| Aug 2007 | $1.92 M(+988.5%) | $1.92 M(+99.1%) |
| May 2007 | - | $963.40 K(+622.2%) |
| Feb 2007 | - | $133.40 K(+84.5%) |
| Nov 2006 | - | $72.30 K(-59.0%) |
| Aug 2006 | $176.20 K | $176.20 K(-7.9%) |
| May 2006 | - | $191.40 K |
FAQ
- What is Oramed Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Oramed Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Oramed Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of ORMP is $9.05 M
What is the all time high annual cash & cash equivalents for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high annual cash & cash equivalents is $77.25 M
What is Oramed Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, ORMP annual cash & cash equivalents has changed by -$31.41 M (-77.62%)
What is Oramed Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ORMP is $42.10 M
What is the all time high quarterly cash and cash equivalents for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high quarterly cash and cash equivalents is $84.75 M
What is Oramed Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, ORMP quarterly cash and cash equivalents has changed by +$33.05 M (+364.98%)